NO20073511L - Ostrogenreseptormodulatorer - Google Patents

Ostrogenreseptormodulatorer

Info

Publication number
NO20073511L
NO20073511L NO20073511A NO20073511A NO20073511L NO 20073511 L NO20073511 L NO 20073511L NO 20073511 A NO20073511 A NO 20073511A NO 20073511 A NO20073511 A NO 20073511A NO 20073511 L NO20073511 L NO 20073511L
Authority
NO
Norway
Prior art keywords
disease
estrogen
compounds
inflammatory bowel
bowel syndrome
Prior art date
Application number
NO20073511A
Other languages
English (en)
Norwegian (no)
Inventor
Mark L Greenlee
Dongfang Meng
Donald M Sperbeck
Kenneth J Wildonger
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20073511L publication Critical patent/NO20073511L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20073511A 2004-12-09 2007-07-06 Ostrogenreseptormodulatorer NO20073511L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63478504P 2004-12-09 2004-12-09
PCT/US2005/043859 WO2006062876A2 (en) 2004-12-09 2005-12-05 Estrogen receptor modulators

Publications (1)

Publication Number Publication Date
NO20073511L true NO20073511L (no) 2007-09-07

Family

ID=36578441

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073511A NO20073511L (no) 2004-12-09 2007-07-06 Ostrogenreseptormodulatorer

Country Status (15)

Country Link
US (1) US7511152B2 (pt)
EP (1) EP1827421B1 (pt)
JP (2) JP2008523065A (pt)
KR (1) KR20070085874A (pt)
CN (1) CN101087606B (pt)
AU (1) AU2005314230B2 (pt)
BR (1) BRPI0518874A2 (pt)
CA (1) CA2590860C (pt)
IL (1) IL183543A (pt)
MX (1) MX2007006878A (pt)
NO (1) NO20073511L (pt)
NZ (1) NZ555316A (pt)
RU (1) RU2394820C2 (pt)
WO (1) WO2006062876A2 (pt)
ZA (1) ZA200704223B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008524221A (ja) * 2004-12-17 2008-07-10 バイオノボ・インコーポレーテッド Ｅｐｉｍｅｄｉｕｍ属植物の抽出液を用いた方法
US7482029B2 (en) * 2005-04-01 2009-01-27 Bionovo, Inc. Composition for treatment of menopause
ATE517871T1 (de) * 2005-10-05 2011-08-15 Merck Sharp & Dohme Östrogenrezeptormodulatoren
US7700136B2 (en) * 2005-11-14 2010-04-20 Bionovo, Inc. Scutellaria barbata extract for the treatment of cancer
EA026578B1 (ru) 2007-01-22 2017-04-28 ДЖиТиЭкс, ИНК. Вещества, связывающие ядерные рецепторы
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US20080319051A1 (en) * 2007-06-22 2008-12-25 Bionovo, Inc. Liquiritigenin and derivatives as selective estrogen receptor beta agonists
US20090042818A1 (en) * 2007-06-22 2009-02-12 Bionovo, Inc. Liquiritigenin and Derivatives as Selective Estrogen Receptor Beta Agonists
JP2010535815A (ja) * 2007-08-08 2010-11-25 バイオノボ・インコーポレーテッド モクセイ科トウネズミモチのエストロゲン性抽出物およびその使用
US20090068299A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. ESTROGENIC EXTRACTS OF Pueraria lobata Willd. Ohwi of the Leguminosae Family AND USES THEREOF
US9155770B2 (en) * 2007-09-07 2015-10-13 Bionovo, Inc. Estrogenic extracts of Scuttelaria barbata D. don of the labiatae family and uses thereof
US9339523B2 (en) * 2007-09-07 2016-05-17 Bionovo, Inc. Estrogenic extracts of Asparagus conchinchinensis (Lour.) Merr of the Liliaceae family and uses thereof
AU2008296072A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. Estrogenic extracts of Astragalus membranaceus Fisch.Bge.Var.mongolicus Bge. of the Leguminosae Family and uses thereof
US20090130101A1 (en) * 2007-11-19 2009-05-21 Bionovo, Inc. Anti-cancer therapy with an extract of scutellaria barbata
EP2222322A4 (en) * 2007-11-19 2012-07-25 Bionovo Inc EXTRACT OF SCUTELLARIA BARBATA AND COMBINATIONS CONTAINING IT FOR THE TREATMENT OF CANCER
WO2009067550A1 (en) 2007-11-19 2009-05-28 Bionovo, Inc. Methods of detecting and treatment of cancers using scuttelaria barbata extract
WO2009070478A2 (en) * 2007-11-19 2009-06-04 Bionovo, Inc. A process of making purified extract of scutellaria barbata d. don
WO2009129260A2 (en) * 2008-04-14 2009-10-22 Bionovo, Inc. Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases
EP2310024A4 (en) * 2008-05-06 2012-07-25 Bionovo Inc ESTROGENIC EXTRACTS FOR THE TREATMENT OF VAGINA AND VULVAATROPHY
CA2726982A1 (en) * 2008-06-05 2009-12-10 Bionovo, Inc. Method of quantification of multiple bioactives from botanical compositions
EP2303249A4 (en) * 2008-06-06 2012-05-30 Bionovo Inc ANTHRAQUINONES AND ANALOGS FROM RHEUM PALMATUM FOR THE TREATMENT OF MEDIA CONDITIONS BY THE STROGEN BETA RECEPTOR
CA2734523A1 (en) * 2008-09-03 2010-03-11 Bionovo, Inc. Methods and compositions for the treatment of cancer
AU2010246233A1 (en) * 2009-04-28 2011-12-22 Bionovo, Inc. Method of reducing fat accumulation and inducing weight loss
CA2932224A1 (en) 2013-12-05 2015-06-11 Karo Pharma Ab Estrogen receptor beta agonists for use in treating mesothelioma
BR112018011817A2 (pt) * 2015-12-22 2018-12-04 Jiangsu Hengrui Medicine Co derivado de benzopiperidina, método de preparação do mesmo, e uso médico do mesmo

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294926A (en) 1979-06-15 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
JPS5889191A (ja) 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
AU570021B2 (en) 1982-11-22 1988-03-03 Novartis Ag Analogs of mevalolactone
US4911165A (en) 1983-01-12 1990-03-27 Ethicon, Inc. Pliabilized polypropylene surgical filaments
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4885314A (en) 1987-06-29 1989-12-05 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4782084A (en) 1987-06-29 1988-11-01 Merck & Co., Inc. HMG-COA reductase inhibitors
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US4916239A (en) 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5118853A (en) 1988-10-13 1992-06-02 Sandoz Ltd. Processes for the synthesis of 3-disubstituted aminoacroleins
US5290946A (en) 1988-10-13 1994-03-01 Sandoz Ltd. Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes
US4929437A (en) 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5189164A (en) 1989-05-22 1993-02-23 Sandoz Ltd. Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DE19523446A1 (de) * 1995-06-28 1997-01-02 Bayer Ag Benzotriazole
KR20010111277A (ko) 1999-03-15 2001-12-17 추후제출 신규한 프로테아제 억제제 화합물 및 조성물
EP1248612B1 (en) 2000-01-06 2008-02-27 Merck Frosst Canada Ltd. Novel compounds and compositions as protease inhibitors
AU784200B2 (en) * 2000-02-14 2006-02-23 Merck Sharp & Dohme Corp. Estrogen receptor modulators
GB0012209D0 (en) 2000-05-19 2000-07-12 Novartis Ag Organic compounds
JP4722375B2 (ja) * 2000-06-20 2011-07-13 ノバルティス アーゲー ビホスホネートの投与法
AU2696502A (en) * 2000-11-27 2002-06-03 Merck & Co Inc Estrogen receptor modulators
CA2456150A1 (en) * 2001-08-13 2003-02-27 Merck & Co., Inc. Selective estrogen receptor modulators
WO2004027031A2 (en) 2002-09-19 2004-04-01 Merck & Co., Inc. Tryptophan hydroxylase assay
AR051597A1 (es) * 2004-11-01 2007-01-24 Merck & Co Inc Moduladores de los receptores de estrogeno

Also Published As

Publication number Publication date
EP1827421A2 (en) 2007-09-05
RU2394820C2 (ru) 2010-07-20
NZ555316A (en) 2009-08-28
RU2007125655A (ru) 2009-01-20
MX2007006878A (es) 2007-06-22
CA2590860A1 (en) 2006-06-15
KR20070085874A (ko) 2007-08-27
JP2012092103A (ja) 2012-05-17
EP1827421A4 (en) 2011-03-30
IL183543A0 (en) 2007-09-20
EP1827421B1 (en) 2017-09-27
US20070265318A1 (en) 2007-11-15
AU2005314230B2 (en) 2011-05-19
IL183543A (en) 2015-03-31
WO2006062876A2 (en) 2006-06-15
JP2008523065A (ja) 2008-07-03
CN101087606A (zh) 2007-12-12
WO2006062876A3 (en) 2006-09-14
US7511152B2 (en) 2009-03-31
ZA200704223B (en) 2008-08-27
CA2590860C (en) 2011-05-03
BRPI0518874A2 (pt) 2008-12-16
CN101087606B (zh) 2010-12-29
AU2005314230A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
NO20073511L (no) Ostrogenreseptormodulatorer
NO20072771L (no) Ostrogenreseptormodulatorer
DK1501819T3 (da) Østrogenreceptormodulatorer
ATE524170T1 (de) Östrogenrezeptor modulatoren
WO2002091993A3 (en) Estrogen receptor modulators
ATE329904T1 (de) Östrogenrezeptormodulatoren
WO2004073612A3 (en) Estrogen receptor modulators
WO2002032377A3 (en) Estrogen receptor modulators
WO2006081152A3 (en) Estrogen receptor modulators
WO2007148330A3 (en) Adjustable orthopedic insoles
IL178561A0 (en) Polymer conjugate releasable under mild thiolytic conditions
ATE517871T1 (de) Östrogenrezeptormodulatoren
WO2004091488A3 (en) Estrogen receptor modulators
WO2002032373A3 (en) Estrogen receptor modulators
WO2005097141A3 (en) Estrogen receptor modulators
WO2004073610A3 (en) Estrogen receptor modulators
WO2008057309A3 (en) Estrogen receptor modulators
ATE301629T1 (de) Estrogenrezeptorliganden und verfahren
AU2003294324A8 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
WO2002058639A3 (en) Pyranoflavonoid compounds and their use as estrogen receptor modulators
WO2004026887A3 (en) Estrogen receptor modulators
DOP2005000224A (es) Moduladores de los receptores de estrogeno
DOP2002000384A (es) Moduladores de receptores estrogenicos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application